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Objectives. The aim of the study was to assess venous reflux and the obstruction pattern after catheter-directed and
systemic thrombolysis of deep iliofemoral venous thrombosis.
Patients. Thirty-two patients treated either with systemic (16) or catheter-directed local thrombolysis (16) for massive
iliofemoral thrombosis were identified from the hospital registry.
Methods. Clinical evaluation at follow up was based on the CEAP classification and disability score. Reflux was assessed by
colour duplex ultrasonography and standardised reflux testing. A vascular surgeon blinded to treatment established the
clinical status of the lower limb following the previous DVT.
Results. Valvular competence was preserved in 44% of patients treated with catheter-directed thrombolysis compared with
13% of those treated with systemic thrombolysis (p ¼ 0.049, Chi squared). Reflux in any deep vein was present in 44% of
patients treated by catheter-directed lysis compared with 81% of patients receiving systemic thrombolysis (p ¼ 0.03, Chi
squared). Reflux in any superficial vein was observed in 25% vs. 63% of the patients, respectively (p ¼ 0.03, Chi squared).
There were significantly more patients with venous insufficiency of classes C0-1 in the group treated with catheter-directed
thrombolysis.
Conclusion. In this clinical series venous valvular function was better preserved after iliofemoral DVTwhen treated with
catheter-directed thrombolysis.
Key Words: Deep venous thrombosis; Catheter-directed thrombolysis; Systemic thrombolysis; Postthrombotic syndrome;
Venous reflux.
Introduction
Approximately two-thirds of patients with iliofemoral
deep venous thrombosis (DVT) will develop post-
thrombotic syndrome (PTS).1 – 3 Appearance of symp-
toms of PTS usually occurs within 1–5 years of the
acute thrombosis, in most of the patients they appear
within the first 2 years.3,4 The development of clinical
signs of PTS is preceded by venous valvular
incompetence.
Standard treatment of acute DVT consists of antic-
oagulation with unfractionated or low molecular
weight heparin followed by oral anticoagulants. The
goal is to prevent the extension of thrombus, pulmon-
ary embolism as well as valvular damage. However,
PTS is reported to occur more frequently in patients
treated with heparin alone compared to patients
treated with the thrombolytic drug streptokinase.5 – 7
Rapid thrombolysis seems to be important in preser-
ving valve function.8,9 Furthermore a lower incidence
of PTS has been seen in patients treated with
recombinant tissue-type plasminogen activator (rt-PA
or alteplase), achieving greater than 50% of lysis.10,11
The thrombolytic drug streptokinase may offer more
complete lysis than standard treatment.12 In a recent
controlled trial systemic thrombolytic therapy both
streptokinase and urokinase, reduced postthrombotic
disability compared with conventional therapy but at
the expense of a serious increase in major bleeding
events and pulmonary emboli.13 Catheter-directed
techniques allow delivery of thrombolytic drug within
the thrombus with the aim of targeted and complete
lysis whist using far lower doses of the drug. In the
case of residual stenosis after lysis, these can often be
treated by transluminal venous balloon angioplasty
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(PTA), stent placement, or both.14 Catheter-directed
thrombolytic therapy has also been reported to achieve
higher venous patency rates and at the same time
being safe.15 Successful catheter-directed thrombolysis
has been associated with a reduction in postthrombo-
tic morbidity.16,17 Both systemic and catheter-directed
thrombolysis are used in clinical practice. To the best
of our knowledge no study exists comparing systemic
and catheter-directed thrombolysis for the treatment
of iliofemoral DVT.
The aim of the present retrospective study was to
compare the prevalence of PTS and reflux patterns in
patients with iliofemoral venous thrombosis treated
either with catheter-directed or systemic thrombolysis.
Therefore we evaluated a clinical series patients
suffering iliofemoral DVT treated either with systemic
or catheter-directed thrombolysis 2–3 years after the
thrombotic event. In this series of patients treatment
was decided upon by the clinicians managing the
patients and this is therefore not a randomised study.
Patients and Methods
Patients
A total of 60 patients with iliofemoral DVT were
retrieved from the Hospital Data Registry of Helsinki
University Central Hospital covering a 1-year period
from July 1999 to the end of June 2000. Out of 60
patients 12 had died since the acute event; four of 12
deceased patients were treated with catheter-directed
thrombolysis, one with systemic thrombolysis and six
without thrombolysis. Of 60 patients 11 were treated
with low molecular weight heparin and anticoagula-
tion without thrombolysis. These 11 patients presented
with clinically less severe thrombosis and were
considered no need of thrombolytic treatment.
Altogether 37 patients treated with thrombolytic
therapy for iliofemoral DVT constituted the study
group. The patients had overt clinical signs and
symptoms of DVT and the initial diagnosis had been
established with compression B-mode ultrasound
imaging. Although the level of the thrombus had
been mapped to extend to the iliofemoral level in
every patient included the study, the retrospective
patient sampling did not allow a detailed analysis of
pre-treatment imaging data. Venography was per-
formed in patients in the catheter-directed lysis group
both before and after lysis. In the systemic lysis group
post-treatment venography was performed only if the
result of the lysis seemed to be clinically inadequate.
Sixteen of 37 patients had been treated with
catheter-directed thrombolysis with recombinant
tissue-type plasminogen activator (rt-PA or alte-
plase), and 16 with systemically administered
thrombolysis either with streptokinase or rt-PA.
There were five patients who received catheter-
directed thrombolysis after initial systemic throm-
bolysis had failed to produce an adequate clinical
result. However this group of five patients was not
included into the analysis because of its small size.
The final study sample thus included 32 patients
(Table 1).
Catheter-directed thrombolysis was performed by
positioning the catheter properly within the throm-
bus. Initially a 10–20 mg bolus of alteplase was
given and continuous infusion of 0.01 mg/kg/h
started. Control phlebography was performed after
24 h of the beginning of the infusion. If there was
fibrotic stenosis or residual thrombus, angioplasty
and stent placement were considered and infusion
was continued for up to 48 h. Three of 16 patients
in the catheter-directed lysis group had residual
stenosis after lysis and were treated with PTA (1
patient), PTA and stenting (1 patient) and catheter
thrombectomy (1 patient). All patients received low
molecular weight heparin and oral anticoagulants in
addition to thrombolytic treatment. rt-PA was used
for catheter-directed lysis as the thrombolytic agent.
In the systemic lysis group, streptokinase was used
in 14 and rt-PA in four patients. In two patients rt-
PA was administered following streptokinase infu-
sion, in one patient due to an acute allergic reaction
to streptokinase and in another due to lack of
thrombolytic effect.
Major bleeding complications and need for blood
transfusions were encountered in 2/16 (13%) of
catheter-directed lysis-treated patients (one retroper-
itoneal bleed and one larger haematoma at the
puncture site) and in 1/16 (6%) of systemic-treated
patients (hematuria). Minor bleeding events, such as
hematomas at the puncture site or other subcutaneous
ecchymosis, were reported in four (25%) of catheter-
directed treated and six (38%) of systemic lysis-treated
patients ðp ¼ 0:20Þ: No intracranial bleeding occurred.
If the clinician found no obvious predisposing
cause or known risk factor for the thrombosis, a
thrombophilia screen was performed. A genetic risk
factor was detected in four of the catheter-directed and
in two of systemic lysis-treated patients. The pro-
thrombotic states were: protein C deficiency, one
patient; lupus anticoagulant, one patient; activated
protein C (APC)-resistance, three patients; prothrom-
bin gene mutation, one patient. ðp ¼ 0:16Þ: No signifi-
cant baseline difference between these two groups was
found.
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Methods
The venous patient questionnaire of Kistner and
Eklof18 was used to identify risk factors. Patients
were also asked to fill in the questionnaire concerning
risk factors, and the duration of anticoagulation
therapy. Risk factors included were genetic thrombo-
philias, previous DVT or pulmonary embolism, obes-
ity (body mass index over 30 kg/m2), regular use of
hormonal replacement therapy or oral contraceptives,
surgery, travelling, immobilization (during 3 months
before onset), and smoking.
The clinical status of the affected leg was classified
from 0 to 6 according to the CEAP classification19,20
and disability score was calculated at follow-up 2–3
years after the acute event.
A detailed systematic duplex ultrasound examin-
ation of the entire venous system from the groin to the
ankle was performed in limbs affected previously by
DVT by an experienced vascular surgeon who was
blinded to the treatment received by the patients.
Patients were studied in the standing position with
their weight on their contralateral foot. Any obstruc-
tion was identified by compression ultrasound. Any
venous segment, which could not be compressed was
considered to be obstructed. Iliac veins were also
examined as proximally as possible, which included
examination of most of the external iliac vein. Colour
duplex ultrasonography was used to detect venous
reflux and gave supplementary information regarding
iliac obstruction. The venous examination was under-
taken using a Hewlett Packard M2410A scanner using
5 MHz probe, and standardised distal pneumatic cuff
release (Venopulse, STR Teknik, Norway) was used to
provoke venous reflux.21 The pathological reflux was
defined as reverse flow lasting one second or more.
Statistical analysis
The statistical measurements were made with the x2
method with no continuity correction. Statistical
significance was defined as a P value of less than
0.05. The Ethics Committee of the Helsinki University
Central Hospital approved this study, and written
informed consent was received from each patient.
Results
There was no difference between groups as to the
length of oral anticoagulation or use of the com-
pression stockings (Table 1). 38% of the patients in
both groups were taking warfarin permanently. Risk
factors, including genetic defects, were found in 50%
of catheter-directed treated and in 75% of systemic-
treated patients (p ¼ 0:25; x2). 50% of the catheter-
directed lysis and 38% of the systemic lysis-treated
patients had used or were still using compression
stockings (p ¼ 0:41; x2).
Patients treated with catheter-directed thromboly-
sis tend to have a better clinical status at follow-up
visit (Table 2). Disability scores (Table 3) did not differ
Table 1. Patient characteristics
Variables Catheter-directed lysis Systemic lysis
No of patients 16 16
No of male 8 6
Age (years) mean and range 56 (21–86) 61 (35–81)
Thrombus age (days) mean and range 3 (1–8) 4 (1–14)
Thrombolytic agents
Alteplase ðnÞ 16 4
Streptokinase (n) 0 14
Total dose of thrombolytic
Alteplase (mg) mean and range 73 (20–142) 229 (100–343)
Streptokinase (IU) mean and range 6.5 £ 106 (2.7–7.4 £ 106)
Duration of thrombolytic therapy (hours) mean and range 33 (12–72) 62 (33–72)
Bleeding
Major 13% (2/16) 6% (1/16)
Minor 25% (4/16) 38% (6/16)
ICH 0 0
Concomitant pulmonary embolism 13% (2/16) 31% (5/16)
Genetic risk factor 25% (4/16) 13% (2/16)
Risk factors* 50% (8/16) 75% (12/16)
The use of compressing stockings 50% (8/16) 38% (6/16)
Warfarin treatment
Permanent warfarin usage 38% (6/16) 38% (6/16)
Duration of warfarin (months) mean and range 8 (3–24) 8 (3–15)
*Presence of one or more of the following risk factors: genetic thrombophilias, previous DVT or pulmonary embolism, obesity, hormones,
smoking, surgery, travelling, immobilization during 3 months before onset.
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significantly between the two groups. 50% of the
patients in catheter-directed thrombolysis group and
31% in systemic thrombolysis group were asympto-
matic (p ¼ 0:28; x2). Five patients in catheter-directed
lysis group (31%) and eight patients in systemic lysis
group (50%) had obstruction in some of the following
veins: long saphenous vein, deep calf veins, popliteal
vein, superficial, deep and common femoral veins,
iliac vein (p ¼ 0:25; x2) (Table 4).
Valvular competence was confirmed in 44% of the
patients treated with catheter-directed thrombolysis
compared with 13% of the systemic thrombolysis-
treated patients (p ¼ 0:049; x2). Deep vein reflux was
present in 44% of catheter-directed lysis-treated
patients compared with 81% of the systemic-treated
patients (p ¼ 0:03; x2). Similarly, patients treated with
catheter-directed thrombolysis had less superficial
vein reflux (25% vs. 63%, p ¼ 0:03; x2) (Fig. 1).
Discussion
Postthrombotic syndrome is a potentially disabling
consequence of DVT. Systemic thrombolytic therapy
has been shown to reduce the incidence of postthrom-
botic sequelae compared with the anticoagulant
therapy alone.5,6,8 Complete lysis has been achieved
with catheter-directed technique in as many as 72%
of patients with proximal DVT.14 Catheter-directed
techniques enable additional management of under-
lying stenosis,16,17 and diminish the incidence of PTS
compared with standard treatment.22 However, the
role of catheter-directed thrombolysis for the treat-
ment of extensive deep venous thrombosis is far from
settled. The present study represents a retrospective
series and its results should be interpreted accord-
ingly. During the particular study period of the present
study there was no consensus on the most useful mode
of thrombolysis for DVT in our institution.
In the present non-randomised study, the baseline
status of the patients prior to treatment decision
appeared comparable. However, potential differences
in the initial status between of groups cannot be
excluded. The outcome might have been confounded
by problems related to management following initial
treatment. Compression stockings are a standard
treatment for DVT and useful in reducing PTS,3 but
this study revealed a clear compliance problem as the
stockings were not used by the patients as advised.
The clinical outcome at 2–3 years after catheter-
directed or systemically administered thrombolytic
therapy for iliofemoral DVT did not differ between the
two treatment groups. However, there appeared to be
Table 2. Clinical classification at the follow up
Clinical class* Catheter-
directed
thrombolysis
Systemic
thrombolysis
n % n %
C0 7 44 2 13
C1 2 13 1 6
C2 1 6 2 13
C3 3 19 6 38
C4 3 19 5 31
C5 0 0 0 0
C6 0 0 0 0
*C0, no visible sign of venous disease; C1, teleangiectases or reticular
formation; C2, varicose veins; C3, oedema; C4, skin changes; C5, skin
changes þ healed ulcer; C6, skin changes þ active ulcer.
Table 3. Clinical disability score at the follow up
Disability score Catheter-directed
thrombolysis
Systemic thrombolysis
n % n %
Asymptomatic 8 50 5 31
Symptomatic, normal activity without support 6 38 8 50
Requires support for normal activity 2 13 3 19
Limited activity even with support 0 0 0 0
Fig. 1. Anatomical distribution of incompetent venous
segments after deep vein thrombosis in patients treated
with catheter-directed thrombolysis (black column) and
systemic thrombolysis (light grey column).
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a trend towards fewer symptoms in the catheter-
directed treatment group. This was true despite the
surprisingly high incidence of residual iliac obstruc-
tion in both groups. It was unclear whether those
obstructions represented post-thrombotic occlusion
from the initial DVT or from an earlier episode.
Other studies have reported distal deep venous
reflux to occur in most postthrombotic legs.23,24
Superficial reflux has been suggested to be the most
important risk factor for early signs of PTS.25 Less
venous incompetence in both deep and superficial
veins was observed in patients with the catheter-
directed thrombolysis than in the systemic thrombo-
lysis-treated patients in the present study. However,
the presence of superficial venous reflux before the
appearance of DVT might have biased the results of
our study especially as no reflux data were available
from the time thrombolysis was started. Nevertheless,
our objective findings may suggest a diminished risk
for PTS in the catheter-lysis-treated group. Indeed, the
immediate treatment results were evaluated more
precisely in patients treated with the catheter-directed
thrombolysis. The control venography also offered an
immediate possibility for the interventional radiol-
ogist to visualise and treat underlying lesion. Actually
we believe that this represents an adjunct to the
invasive approach.
Valvular incompetence is most often found in the
superficial femoral and popliteal vein level.26 Our
results were in accordance with those findings. Earlier
it has been reported that more than two-third of the
patients develop valvular incompetence during the
first year of the acute event.27 Thus the 2–3 year follow
up time of the present study should be adequate for
detecting PTS.
The present study did not allow comparison of
specific drugs and dosages but rather the modes of
treatment in current practice at the time of the study.
Only rt-PA is used in catheter-directed lysis in our
hospital. In systemic lysis both rt-PA and streptokinase
have been used, although the use of streptokinase has
diminished during the past few years. However, in
systemic lysis group the doses of the thrombolytic
agents were higher and the duration of treatment
longer. Recently, low-dose rt-PA (21.2 SD 15.1 mg)
combined with sub-therapeutic heparin and urokinase
4.5 SD 2.4 £ 106 U with full heparin have been
reported to be equally efficacious in catheter-directed
thrombolysis.28 In this study no significant difference
with the bleeding complications occurred between
catheter-directed and systemic thrombolysis
treatment.
Patients treated only with anticoagulation were
excluded from the study because they were likely to
have less profound thrombosis and clinical signs and
symptoms. A long term follow-up study of patients
with iliofemoral DVT treated with heparin has indeed
shown quite low rates of PTS.29 Patients suffering
concomitant DVT and clinically significant pulmonary
embolism, received systemic thrombolysis more often
than catheter-directed lysis.
Conclusions
Patients treated with catheter-directed thrombolysis
for their iliofemoral DVT at the acute event had
significantly reduced less both deep and superficial
reflux at 2–3 years follow up. This study suggests that
catheter-directed thrombolysis may be superior to
systemic thrombolysis in preserving venous valvular
function in the clinical practice of treating iliofemoral
DVT. Our data must be interpreted cautiously since it
remains possible that the patient groups may have
been different in the first place.
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